Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma CDMO offers integrated end-to-end solutions for development & commercialization of intermediates & APIs for small molecules.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    veranova-m-2025-06-30

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Savolitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Hutchmed Completes Patient Enrollment for Savolitinib Study
    Hutchmed Completes Patient Enrollment for Savolitinib Study

    21 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/22/3065080/0/en/HUTCHMED-Completes-Patient-Enrollment-of-a-Phase-II-Registration-Study-of-Savolitinib-in-Gastric-Cancer-in-China.html

    GLOBENEWSWIRE
    21 Apr 2025
    Share Share
    HUTCHMED Highlights Savolitinib SAVANNAH Ph 2 At ELCC 2025
    HUTCHMED Highlights Savolitinib SAVANNAH Ph 2 At ELCC 2025

    19 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/20/3045892/0/en/HUTCHMED-Highlights-Savolitinib-SAVANNAH-Phase-II-and-Other-Data-at-European-Lung-Cancer-Congress-2025.html

    GLOBENEWSWIRE
    19 Mar 2025
    Share Share
    HUTCHMED Gets NMPA Approval For ORPATHYS® In MET Exon 14 NSCLC
    HUTCHMED Gets NMPA Approval For ORPATHYS® In MET Exon 14 NSCLC

    13 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/14/3008991/0/en/HUTCHMED-Announces-NMPA-Full-Approval-for-ORPATHYS-savolitinib-in-China-for-Patients-with-Locally-Advanced-or-Metastatic-MET-Exon-14-NSCLC.html

    GLOBENEWSWIRE
    13 Jan 2025
    Share Share
    Hutchmed's Priority Review For Orpathys-Tagrisso In Lung Cancer
    Hutchmed's Priority Review For Orpathys-Tagrisso In Lung Cancer

    01 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/02/3003295/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-with-Priority-Review-Status-for-ORPATHYS-and-TAGRISSO-Combination-in-Lung-Cancer-Patients-with-MET-amplification-After-Progression-on-Fir.html

    GLOBENEWSWIRE
    01 Jan 2025
    Share Share
    Hutchmed Announces Breakthrough Designation for Orpathys & Tagrisso
    Hutchmed Announces Breakthrough Designation for Orpathys & Tagrisso

    11 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/12/2995863/0/en/HUTCHMED-Announces-Breakthrough-Therapy-Designation-in-China-for-ORPATHYS-and-TAGRISSO-Combination-in-Certain-Lung-Cancer-Patients-After-Disease-Progression-on-EGFR-Inhibitor-Thera.html

    GLOBENEWSWIRE
    11 Dec 2024
    Share Share
    Hutchmed's ORPATHYS® Maintains Inclusion In China’s NDL
    Hutchmed's ORPATHYS® Maintains Inclusion In China’s NDL

    28 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/28/2988577/0/en/HUTCHMED-Announces-Continued-Inclusion-of-ORPATHYS-savolitinib-in-the-National-Reimbursement-Drug-List-in-China-at-Current-Terms.html

    GLOBENEWSWIRE
    28 Nov 2024
    Share Share